Albany NY (March 14, 2013) (CULRAV.ORG) -
New Report Added in ResearchMoz Reports Database Acquired Orphan Blood Diseases Therapeutics Market to 2019 – Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential.
To Browse Full TOC, Tables & Figures visit: http://www.researchmoz.us/acquired-orphan-blood-diseases-therapeutics-market-to-2019-search-for-disease-modifying-drugs-central-to-unlocking-premium-pricing-potential-report.html
GBI Research, has released its latest research, Acquired Orphan Blood Diseases Therapeutics Market to 2019 Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential. The report provides insights into the up-and-coming trends of a portion of the acquired orphan blood disorder pharmaceutical market by examining Idiopathic Thrombocytopenic Purpura (ITP), Myelodysplastic Syndrome (MDS), Myelofibrosis (MF), Paroxysmal Nocturnal Hemoglobinuria (PNH) and Polycythemia Vera (PV) in seven major markets: the US, the top five European countries (France, Germany, Italy, Spain and the UK) and Japan.
- Current and future treatment trends for three rare diseases
- Market forecasts for five rare diseases across seven major markets
- Analysis of the developmental pipelines for five rare diseases
- Information on recent industry deals
- Understand how the inherited orphan blood diseases market has developed and is continuing to develop within the featured markets
- Predict which products are likely to be most successful in the future
- Gain an understanding of the possible market available for specific products
Cellular Therapy and Cord Blood 2013 Market Report @ http://www.researchmoz.us/cellular-therapy-and-cord-blood-report.html
This is the most up-to-date market report focusing on Cellular Therapy and the HSCT/Cord Blood Market Landscape, published by Select Biosciences. In this comprehensive market report, we have focused primarily on quantitative market metrics in order to characterize the growth and evolution of the cellular therapy field–in this vein, we present primary industry data that Select Biosciences has collected as part of its continual industry tracking of this space.We’ve analyzed clinical trial trends and the evolution of several therapeutics areas within cellular therapy [orthopedic, skin/wound care, cardiovascular, and CNS disorders] and present the current status of every single program within the preclinical through the various clinical trial phases and onto commercialization. We also present the breakout of clinical trials in the bona fide cellular therapy sector with respect to geographic breakout, breakout by type of cells utilized, and disease classes interrogated.Select Biosciences has also provided a detailed quantitative analysis of the cord blood field as it is rapidly evolving. Our coverage provides hard numbers on sizes of the various registries, the TNC breakouts of banked units, detailed cost breakouts for banking as well as HSCTs utilizing cord blood. Furthermore, given our global footprint, we’ve been able to compare the EU and US markets side-by-side in this analysis.
Inherited Orphan Blood Disorders Therapeutics Market to 2019 – Breakthrough Drugs Remain Elusive Against Backdrop of High Unmet Need @ http://www.researchmoz.us/inherited-orphan-blood-disorders-therapeutics-market-to-2019-breakthrough-drugs-remain-elusive-against-backdrop-of-high-unmet-need-report.html
GBI Research, the leading business intelligence provider, has released its latest research, Inherited Orphan Blood Disorders Therapeutics Market to 2019 Breakthrough Drugs Remain Elusive Against Backdrop of High Unmet Need. The report provides insights into the up-and-coming trends of a portion of the inherited orphan blood disorder pharmaceutical market by examining sickle cell anemia, thalassemia and Hereditary Angioedema (HAE) in seven major markets: the US, the top five European countries (France, Germany, Italy, Spain and the UK) and Japan. The report includes market forecasts to 2019, detailed pipeline analysis, in-depth profiling of major products and details of recent industry deals.The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Researchs team of industry experts.The sickle cell anemia market will be the fastest growing of the three markets during the forecast period with a Compound Annual Growth Rate (CAGR) of 9% seeing it reach $70m in 2019. The thalassemia market will grow at a lower CAGR of 7% to reach $59m in 2019. HAE represents the largest but slowest growing market, expected to reach $1.89 billion by 2019 at a CAGR of 3%.
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
90 Sate Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-997-4948